A half-decade after a scientist’s reckless experiment with human embryos put a stop to much of China’s clinical work on CRISPR gene editing, local researchers are once again performing human studies of the technology.
At least three Chinese biotech companies have recently begun tests of CRISPR treatments for blood, eye and liver diseases, with more on the way. Although most are pursuing the same set of well-trodden targets as their US counterparts, they are moving at rapid speed and with a fraction of the funding of their Western peers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.